The Kraft Group

The Kraft Group is a privately-owned, family-operated holding company with a diverse range of interests concentrated in five key areas: paper and packaging manufacturing, sports and entertainment, real estate development, private equity investing, and philanthropy. With over 5,000 employees and operations in more than 80 countries, The Kraft Group boasts a global presence that includes manufacturing and distribution facilities, executive offices, and sports stadiums across four continents. The company emphasizes a strong commitment to customer focus, driven by family members and trusted staff who prioritize responsiveness and independence. In addition to its business ventures, Kraft Sports + Entertainment provides concerts and sporting events to the New England community, further highlighting the company's dedication to integrating entertainment with its broader business objectives.

Robert Kraft

Founder, Chairman and CEO

Daniel Kraft

President, International

William M. Scalzulli

Vice President of Investments

45 past transactions

Claim

Seed Round in 2023
Claim operates a social shopping application designed to enhance brand discovery for consumers, particularly targeting Gen Z. The platform allows brands to engage directly in customer acquisition through weekly promotional events known as Drops, which showcase new products. Users can earn rewards such as cash-back, exclusive event access, and free merchandise simply by shopping at their favorite brands. Additionally, Claim encourages social interaction by enabling users to share benefits with friends through gifting and trading rewards. This approach aims to create a fun and engaging shopping experience that connects consumers with brands in a meaningful way.

Prolific Machines

Series A in 2022
Prolific Machines is a biotechnology company based in San Francisco, California, founded in 2020. It specializes in developing advanced cell technologies aimed at transforming the production of cells for sustainable applications, particularly in the cultivated meat industry. The company focuses on high-scale precision cell-differentiation techniques that enhance the efficiency, quality, reproducibility, and sustainability of cell production. Additionally, Prolific Machines is engaged in research and development efforts related to clean meat and cell therapies, utilizing innovative approaches to create better sustainable options. Through its work, the company aims to promote a healthier future for both humanity and the planet.

Stackwell

Seed Round in 2022
Stackwell Capital is a fintech firm focused on providing a digital investment platform specifically for the Black community, aiming to address and reduce the racial wealth gap in America. By offering essential financial tools and guidance, Stackwell seeks to promote long-term wealth creation, equity, and equal opportunities. The platform incorporates principles of behavioral psychology and efficient portfolio construction to enhance participation and investment among Black Americans, addressing trust issues that have historically led to underinvestment. Additionally, it features automated portfolio construction and educational resources within the app to help overcome social and emotional barriers to financial asset ownership. Stackwell is also involved in accelerator programs aimed at fostering innovation in financial solutions.

CAMP4 Therapeutics

Series B in 2022
CAMP4 Therapeutics Corporation, based in Cambridge, Massachusetts, specializes in bioinformatics and gene regulation circuitry. Founded in 2015, the company has developed a 4-D gene circuitry platform that translates the activation of the human genome's 24,000 genes into a set of combinatorial rules based on existing signaling pathways. This innovative approach allows CAMP4 to control gene expression effectively, addressing the root causes of diseases. By leveraging this gene circuitry code, the company aims to expedite the drug development process, significantly reducing both time and risk associated with bringing new treatments to patients.

Evolved By Nature

Series C in 2022
Evolved By Nature, Inc. is a biotech company based in Medford, Massachusetts, specializing in the development of Activated Silk technology, which utilizes silk protein derived from discarded silkworm cocoons. Founded in 2013 by biomedical engineer Rebecca Lacouture and chemist Gregory Altman, the company aims to create sustainable and effective alternatives to traditional chemicals used in various industries. Evolved By Nature manufactures products for textiles, personal care, and medical applications, focusing on enhancing performance while reducing reliance on harmful substances. Its innovative liquid silk technology delivers pure silk molecules, offering advanced anti-aging benefits in skincare without synthetic fillers or harsh preservatives. Since its inception, the company has secured numerous patents for its molecular combinations, underscoring its commitment to advancing health for both people and the planet.

Jackpot

Series A in 2022
Jackpot.com is modernizing the way Americans play the lottery. Jackpot.com brings verified, official state lottery tickets online by leveraging its digital platform to give customers the ability to play right from your phone, tablet, or desktop. Jackpot.com has invested significantly in responsible gaming safeguards, with default spending limits and other features built in throughout the experience, which earned them a certification from the National Council on Problem Gaming. To learn more, visit jackpot.com or download the iOS or Android app.

Relief

Series A in 2022
Relief is a mobile app that delivers on debt-elimination commitment. They aim to become the company that people come to for help getting back in the black. By developing products and services that are simple, effective, and easy to use, they will make financial relief accessible to those who need it.

Wagr

Series A in 2022
Wagr is an online sports betting mobile application based in the United States. The platform enables users to make and share sports bets with friends, facilitating social interaction within the betting experience. Users can challenge friends, create groups, and track leaderboards, effectively blending social media features with sports betting. By focusing on the social aspects of gambling, Wagr aims to engage users in a rapidly expanding market.

Evolved By Nature

Series B in 2021
Evolved By Nature, Inc. is a biotech company based in Medford, Massachusetts, specializing in the development of Activated Silk technology, which utilizes silk protein derived from discarded silkworm cocoons. Founded in 2013 by biomedical engineer Rebecca Lacouture and chemist Gregory Altman, the company aims to create sustainable and effective alternatives to traditional chemicals used in various industries. Evolved By Nature manufactures products for textiles, personal care, and medical applications, focusing on enhancing performance while reducing reliance on harmful substances. Its innovative liquid silk technology delivers pure silk molecules, offering advanced anti-aging benefits in skincare without synthetic fillers or harsh preservatives. Since its inception, the company has secured numerous patents for its molecular combinations, underscoring its commitment to advancing health for both people and the planet.

Mythical Games

Series C in 2021
Mythical Games Inc. is a game technology studio founded in 2018 and based in Sherman Oaks, California, with an additional office in Seattle, Washington. The company develops blockchain-based games and aims to create a new generation of gaming experiences by enabling true ownership of digital assets, verifiable scarcity, and integrated secondary markets. Its flagship title, Blankos, is a casual multiplayer game where players can buy, trade, and sell their unique designs. Mythical Games also provides tools for content creators and brands, allowing them to customize and own game assets. By fostering a decentralized gaming ecosystem, the company brings players, developers, and content creators together, promoting personalized experiences and driving consumer adoption of distributed ledger technology through innovative gaming products.

CAMP4 Therapeutics

Series A in 2021
CAMP4 Therapeutics Corporation, based in Cambridge, Massachusetts, specializes in bioinformatics and gene regulation circuitry. Founded in 2015, the company has developed a 4-D gene circuitry platform that translates the activation of the human genome's 24,000 genes into a set of combinatorial rules based on existing signaling pathways. This innovative approach allows CAMP4 to control gene expression effectively, addressing the root causes of diseases. By leveraging this gene circuitry code, the company aims to expedite the drug development process, significantly reducing both time and risk associated with bringing new treatments to patients.

Premier Lacrosse League

Series C in 2021
Premier Lacrosse League is a professional lacrosse organization in North America that aims to elevate the sport through a tour-based model. It features a roster of top players, showcasing the biggest stars in lacrosse and providing fans with an engaging entertainment experience. By operating a series of tournaments, the league seeks to bring lacrosse to a national audience, promoting its growth and popularity. In addition to its events, Premier Lacrosse League also sells sports-related apparel online, further connecting with its fanbase and enhancing the overall lacrosse experience.

Rowdy Energy

Funding Round in 2021
Rowdy Energy is a company that specializes in the production of energy drinks aimed at enhancing focus and performance. Its drinks combine caffeine with the nootropic L-Theanine, which helps provide a boost in energy without the common crash associated with many energy beverages. The inclusion of electrolytes supports hydration and maintains optimal body function. Rowdy Energy offers a diverse range of flavors, including seven sugar-free, KETO-certified options. In addition to its beverage line, the company also produces clothing and accessories, catering to consumers seeking a lifestyle that promotes energy and wellness.

ProMIS Neurosciences

Post in 2021
ProMIS Neurosciences, Inc. is a development-stage biotechnology company based in Toronto, Canada, focused on developing precision therapeutic solutions for neurodegenerative diseases, primarily Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson’s disease (PD). Established in 2004, the company employs a proprietary target discovery engine that integrates thermodynamic and computational techniques to identify disease-specific epitopes on misfolded proteins. Its lead product candidates include PMN310, PMN350, and PMN330, which are monoclonal antibodies targeting toxic forms of amyloid beta oligomers and prion-like proteins associated with AD. Additionally, ProMIS is developing treatments targeting the neurotoxic tau protein in AD and proteins linked to ALS and PD. The company collaborates with BC Neuroimmunology to advance proprietary diagnostic assays and blood-based tests for Alzheimer’s disease, enhancing early detection and treatment efficacy. Formerly known as Amorfix Life Sciences Ltd., ProMIS Neurosciences has rebranded itself to reflect its focus on neurological therapeutics.

River

Series A in 2021
River Financial Inc. is a financial technology company based in San Francisco, California, founded in 2019 by Alexander Leishman and Andrew Benson. The company specializes in providing a platform for individuals and institutions to buy, manage, and sell bitcoin. Its flagship product is a Bitcoin brokerage designed for sophisticated retail investors, offering a high-touch service that prioritizes security and client experience. River Financial's platform includes tools for investment performance, such as cost basis tracking, catering to the needs of its clients in the evolving cryptocurrency market.

Songclip (Audiobyte)

Venture Round in 2021
Songclip™ is a new licensed music format built specifically for texting, social posts, and quick communication. Songclip’s multi-patented networked product solution, the Songclip API, integrates seamlessly into social platforms, mobile apps, and virtual marketplaces to drive expression, monetization, and music streaming. Songclip operates the world’s foremost searchable library of 5-30 second meta-tagged music clips, in partnership with the music industry. For more information, visit songclip.com

AUI™ (Augmented Intelligence)

Funding Round in 2021
Delegate is a technology company based in San Francisco, California, with additional offices in Boston, Massachusetts, and Beersheba, Israel. It specializes in a software application designed to manage personal tasks and assignments efficiently. The company offers an innovative service known as "Chief of Stuff," which provides users with a comprehensive solution for handling various personal responsibilities. By combining advanced artificial intelligence with human expertise, Delegate ensures that tasks are completed with high quality and convenience. The aim is to make these services affordable, allowing individuals to focus on what truly matters to them while delegating other tasks to the company.

Butler Hospitality

Series A in 2020
Butler Hospitality is an on-demand platform for room service and amenities. Butler Hospitality delivers amazing gourmet amenities right to any hotel room and specializes in providing offsite room service for limited-service hotels. Butler Hospitality was founded in 2017 in New York City.

Silk Therapeutics

Series B in 2018
Silk Therapeutics develops, manufactures, and sells skincare products based on silk materials. It offers PureProC, a film formulation that surrounds, protects, stabilizes, and delivers the benefits of vitamin C for an extended duration with anti-aging and skin health benefits. The company sells its products through its online store. Silk Therapeutics skincare line features clean, highly effective anti-aging skincare and skin health products that are healthy enough to use on any skin type, including highly sensitive skin. The company's proprietary liquid silk technology platform was developed by company co-founders Greg Altman, Ph.D., and Rebecca Horan, Ph.D., foremost experts in the use of silk for health and wellness solutions—including effective stabilization and delivery of real silk molecules to the skin. Silk Therapeutics, Inc. was incorporated in 2013 and is based in Medford, Massachusetts.

CAMP4 Therapeutics

Series A in 2018
CAMP4 Therapeutics Corporation, based in Cambridge, Massachusetts, specializes in bioinformatics and gene regulation circuitry. Founded in 2015, the company has developed a 4-D gene circuitry platform that translates the activation of the human genome's 24,000 genes into a set of combinatorial rules based on existing signaling pathways. This innovative approach allows CAMP4 to control gene expression effectively, addressing the root causes of diseases. By leveraging this gene circuitry code, the company aims to expedite the drug development process, significantly reducing both time and risk associated with bringing new treatments to patients.

Scholar Rock

Series C in 2018
Scholar Rock is a biotechnology company focused on discovering and developing innovative therapies that target dysregulated growth factors within disease microenvironments. Founded in 2012 and based in Cambridge, Massachusetts, the company employs a proprietary platform to create monoclonal antibodies that selectively modulate the activation of these signaling proteins. This approach aims to avoid traditional challenges associated with growth factor inhibition while facilitating efficient drug development. Scholar Rock's lead product, SRK-015, is designed as a first-in-class inhibitor of myostatin activation, targeting conditions such as spinal muscular atrophy. The company's pipeline includes additional candidates, such as SRK-181, which inhibits latent transforming growth factor beta-1 for cancer treatment. Scholar Rock's research focuses on serious diseases, including neuromuscular disorders, cancer, fibrosis, and autoimmune diseases, reflecting its commitment to transforming patient outcomes through targeted therapies.

Silk Therapeutics

Series A in 2017
Silk Therapeutics develops, manufactures, and sells skincare products based on silk materials. It offers PureProC, a film formulation that surrounds, protects, stabilizes, and delivers the benefits of vitamin C for an extended duration with anti-aging and skin health benefits. The company sells its products through its online store. Silk Therapeutics skincare line features clean, highly effective anti-aging skincare and skin health products that are healthy enough to use on any skin type, including highly sensitive skin. The company's proprietary liquid silk technology platform was developed by company co-founders Greg Altman, Ph.D., and Rebecca Horan, Ph.D., foremost experts in the use of silk for health and wellness solutions—including effective stabilization and delivery of real silk molecules to the skin. Silk Therapeutics, Inc. was incorporated in 2013 and is based in Medford, Massachusetts.

Dune Medical Devices

Series D in 2017
Dune Medical Devices, established in 2002, specializes in tissue characterization technology aimed at enhancing cancer detection during surgical procedures. The company has developed the MarginProbe™ System, which utilizes radiofrequency spectroscopy to provide real-time assessments of excised tissue, helping surgeons determine whether cancerous margins have been adequately removed. This innovative approach addresses a critical concern for oncological surgeons, particularly in breast cancer treatment, by enabling them to make informed decisions during surgery, thus potentially reducing the need for reoperations. In a study involving 300 breast cancer patients in Israel, the use of the MarginProbe System resulted in a 56% reduction in reoperation rates compared to standard practices. Dune Medical Devices' solutions focus on improving the cancer care experience by consistently differentiating between cancerous and healthy tissue, ultimately aiming to enhance patient outcomes.

Spero Therapeutics

Series C in 2017
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases. Founded in 2013, the company is advancing several product candidates, including tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic aimed at treating MDR gram-negative infections in adults. Additionally, Spero is developing SPR206, an intravenous agent for MDR gram-negative infections in hospital settings, and SPR720, an oral antibiotic targeting pulmonary non-tuberculous mycobacterial disease. The company collaborates with various partners, including Meiji Seika Pharma to support tebipenem HBr's development and the Bill & Melinda Gates Medical Research Institute for SPR720. Spero Therapeutics employs a focused approach to drug development, emphasizing novel mechanisms to address the urgent need for effective therapeutics against serious bacterial infections.

Silk Therapeutics

Series A in 2016
Silk Therapeutics develops, manufactures, and sells skincare products based on silk materials. It offers PureProC, a film formulation that surrounds, protects, stabilizes, and delivers the benefits of vitamin C for an extended duration with anti-aging and skin health benefits. The company sells its products through its online store. Silk Therapeutics skincare line features clean, highly effective anti-aging skincare and skin health products that are healthy enough to use on any skin type, including highly sensitive skin. The company's proprietary liquid silk technology platform was developed by company co-founders Greg Altman, Ph.D., and Rebecca Horan, Ph.D., foremost experts in the use of silk for health and wellness solutions—including effective stabilization and delivery of real silk molecules to the skin. Silk Therapeutics, Inc. was incorporated in 2013 and is based in Medford, Massachusetts.

Spero Therapeutics

Series B in 2016
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases. Founded in 2013, the company is advancing several product candidates, including tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic aimed at treating MDR gram-negative infections in adults. Additionally, Spero is developing SPR206, an intravenous agent for MDR gram-negative infections in hospital settings, and SPR720, an oral antibiotic targeting pulmonary non-tuberculous mycobacterial disease. The company collaborates with various partners, including Meiji Seika Pharma to support tebipenem HBr's development and the Bill & Melinda Gates Medical Research Institute for SPR720. Spero Therapeutics employs a focused approach to drug development, emphasizing novel mechanisms to address the urgent need for effective therapeutics against serious bacterial infections.

Skillz

Series B in 2015
Skillz is a mobile games platform focused on enhancing competition through engaging gameplay. It enables game developers to create successful franchises by facilitating social competition within their games. Utilizing patented technology, Skillz hosts billions of casual gaming tournaments, attracting millions of players globally. As a leader in skill-based mobile gaming, the company offers a variety of games, including Dominoes Gold, Blackout Bingo, 21 Blitz, and Solitaire Cube. Skillz operates primarily through its eSports gaming platform, which allows developers to monetize their content via multiplayer competitions. The company generates most of its revenue from the United States, with additional income from international markets such as Israel, China, and Malta. Skillz has received recognition for its workplace culture and innovation in the technology sector.

DraftKings

Series D in 2015
DraftKings Inc. is a digital sports entertainment and gaming company based in Boston, Massachusetts. Founded in 2011, it initially focused on daily fantasy sports contests for cash prizes across major sports in the United States and Canada. Following the 2018 Supreme Court ruling that allowed states to legalize online sports wagering, DraftKings expanded its offerings to include online sports betting and casino gaming. Currently, the company operates in 27 states for online or retail sports betting and in seven states for iGaming, reaching approximately 40% of Canada's population. In addition to its core gaming services, DraftKings designs and develops software for sports betting and casino gaming platforms, and it also manages a marketplace for non-fungible tokens.

Delphix

Series D in 2015
Delphix is a technology company that offers an intelligent data platform designed to facilitate digital transformation for enterprises globally. Founded in 2008 and headquartered in Redwood City, California, Delphix specializes in test data management software that supports a wide range of systems, including mainframes, Oracle databases, ERP applications, and Kubernetes containers. Its DataOps platform enables businesses to accelerate cloud migrations, custom development, and ERP rollouts by providing agile data management capabilities. By eliminating redundant infrastructure and streamlining processes, Delphix helps organizations in sectors such as financial services, telecommunications, consumer packaged goods, e-commerce, and manufacturing to effectively visualize and deliver data across major databases and data warehouses.

Spero Therapeutics

Series A in 2015
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases. Founded in 2013, the company is advancing several product candidates, including tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic aimed at treating MDR gram-negative infections in adults. Additionally, Spero is developing SPR206, an intravenous agent for MDR gram-negative infections in hospital settings, and SPR720, an oral antibiotic targeting pulmonary non-tuberculous mycobacterial disease. The company collaborates with various partners, including Meiji Seika Pharma to support tebipenem HBr's development and the Bill & Melinda Gates Medical Research Institute for SPR720. Spero Therapeutics employs a focused approach to drug development, emphasizing novel mechanisms to address the urgent need for effective therapeutics against serious bacterial infections.

Silk Therapeutics

Series A in 2015
Silk Therapeutics develops, manufactures, and sells skincare products based on silk materials. It offers PureProC, a film formulation that surrounds, protects, stabilizes, and delivers the benefits of vitamin C for an extended duration with anti-aging and skin health benefits. The company sells its products through its online store. Silk Therapeutics skincare line features clean, highly effective anti-aging skincare and skin health products that are healthy enough to use on any skin type, including highly sensitive skin. The company's proprietary liquid silk technology platform was developed by company co-founders Greg Altman, Ph.D., and Rebecca Horan, Ph.D., foremost experts in the use of silk for health and wellness solutions—including effective stabilization and delivery of real silk molecules to the skin. Silk Therapeutics, Inc. was incorporated in 2013 and is based in Medford, Massachusetts.

Lineage Labs

Seed Round in 2015
We are inventors, marketers, consumers, photo buffs, friends, and co-workers. We are dedicated to helping you tell your family's stories. Whether it’s a picture from a day at the beach, or a video of the dog chasing a squirrel, there exists a special, unique story behind all of these images. But too often, due to our busy lives, these stories remain locked away on our digital devices, rarely finding the right way or the right time to be shared and enjoyed.

Scholar Rock

Series A in 2014
Scholar Rock is a biotechnology company focused on discovering and developing innovative therapies that target dysregulated growth factors within disease microenvironments. Founded in 2012 and based in Cambridge, Massachusetts, the company employs a proprietary platform to create monoclonal antibodies that selectively modulate the activation of these signaling proteins. This approach aims to avoid traditional challenges associated with growth factor inhibition while facilitating efficient drug development. Scholar Rock's lead product, SRK-015, is designed as a first-in-class inhibitor of myostatin activation, targeting conditions such as spinal muscular atrophy. The company's pipeline includes additional candidates, such as SRK-181, which inhibits latent transforming growth factor beta-1 for cancer treatment. Scholar Rock's research focuses on serious diseases, including neuromuscular disorders, cancer, fibrosis, and autoimmune diseases, reflecting its commitment to transforming patient outcomes through targeted therapies.

Dune Medical Devices

Series C in 2014
Dune Medical Devices, established in 2002, specializes in tissue characterization technology aimed at enhancing cancer detection during surgical procedures. The company has developed the MarginProbe™ System, which utilizes radiofrequency spectroscopy to provide real-time assessments of excised tissue, helping surgeons determine whether cancerous margins have been adequately removed. This innovative approach addresses a critical concern for oncological surgeons, particularly in breast cancer treatment, by enabling them to make informed decisions during surgery, thus potentially reducing the need for reoperations. In a study involving 300 breast cancer patients in Israel, the use of the MarginProbe System resulted in a 56% reduction in reoperation rates compared to standard practices. Dune Medical Devices' solutions focus on improving the cancer care experience by consistently differentiating between cancerous and healthy tissue, ultimately aiming to enhance patient outcomes.

Sample6

Series B in 2013
Sample6 is a biotechnology company that specializes in the development of a synthetic-biology based diagnostic system for bacteria. Its innovative technology enables enrichment-free detection of harmful bacteria, identifying levels as low as 1 CFU/ml within just four hours. The proprietary Bioillumination Platform, created by a team of researchers including Professor Tim Lu from MIT, allows for the engineering of bioparticles that target specific unwanted bacteria, illuminating them for detection. This system is coupled with sensitive sensor technology that provides rapid on-site results without the need for a laboratory. Sample6 aims to enhance public health and safety by enabling quick and efficient detection of harmful bacteria across various industries, including food production, retail, and healthcare, addressing environments where humans and bacteria interact.

SynapDx

Venture Round in 2013
SynapDx is a laboratory testing service provider focused on the early detection of autism spectrum disorders (ASDs) in children. Founded by Stanley Lapidus, the company aims to assist physicians in evaluating developmental disorders through innovative blood-based diagnostic tests and equipment. By collaborating with experts in ASD and gene expression from prominent institutions, SynapDx seeks to enhance the capability of healthcare providers to identify early symptoms of autism. The company is headquartered in Lexington, Massachusetts, and has secured funding from notable investors, including North Bridge Venture Partners, Bain Capital Ventures, and General Catalyst Partners.

SynapDx

Venture Round in 2013
SynapDx is a laboratory testing service provider focused on the early detection of autism spectrum disorders (ASDs) in children. Founded by Stanley Lapidus, the company aims to assist physicians in evaluating developmental disorders through innovative blood-based diagnostic tests and equipment. By collaborating with experts in ASD and gene expression from prominent institutions, SynapDx seeks to enhance the capability of healthcare providers to identify early symptoms of autism. The company is headquartered in Lexington, Massachusetts, and has secured funding from notable investors, including North Bridge Venture Partners, Bain Capital Ventures, and General Catalyst Partners.

New-Indy Containerboard

Seed Round in 2013
New-Indy Containerboard is a manufacturer and supplier of recycled containerboard specifically for the corrugated box industry. Established in 2012 as a joint venture between the Kraft Group and Schwarz Partners, LP, both of which are family-owned companies with extensive backgrounds in paper and packaging, New-Indy has developed a significant presence in the market. The company operates three recycled brown paper mills and eight packaging facilities across the United States, focusing on sustainability and the efficient production of containerboard products.

Humedica

Venture Round in 2012
Humedica is a clinical intelligence company that specializes in health analytics, providing tools for hospitals, physicians, and life sciences organizations. The company's primary offering, Humedica MinedShare, is a platform designed to transform unconnected data from various sources into actionable insights, enabling clients to make better-informed decisions. By facilitating clinical, operational, and financial benchmarking across the continuum of care, Humedica supports healthcare providers in enhancing the quality and efficiency of their services.

Blog Talk Radio

Series B in 2010
BlogTalkRadio, founded in 2006, is a site where anyone can set up a podcast or "radio talkshow" over the web. Users are given a phone number and can allow anyone to join (and optionally participate) in the call.

Patriot Place

Venture Round in 2010
Patriot Place is a lifestyle center that offers dining, lodging, hospitality, shopping, entertainment and health care.

Acetylon Pharmaceuticals

Series A in 2009
Acetylon Pharmaceuticals, Inc. is focused on developing small molecule drugs that target epigenetic mechanisms to improve therapeutic outcomes in cancer and other serious diseases. Established in 2008 and headquartered in Boston, Massachusetts, the company has created a proprietary platform that has led to a portfolio of optimized selective compounds for oral administration, specifically targeting Class I and Class II histone deacetylases. Among its lead drug candidates are ACY-1215 and ACY-241, which are selective HDAC6 inhibitors currently undergoing Phase 2 and Phase 1b clinical trials for the treatment of multiple myeloma. Acetylon Pharmaceuticals operates as a subsidiary of Celgene Corporation, emphasizing its commitment to addressing critical unmet medical needs through innovative epigenetic therapies.

Blog Talk Radio

Series A in 2008
BlogTalkRadio, founded in 2006, is a site where anyone can set up a podcast or "radio talkshow" over the web. Users are given a phone number and can allow anyone to join (and optionally participate) in the call.

MatchMine

Series A in 2007
MatchMine is a media recommendation service that categorizes and analyzes your media likes and dislikes in order to serve you content that is more to your taste. Through its "MatchKey" technology, Matchmine uses demographic information about each user combined with a rating system to recommend media based upon your past media consumption. MatchMine will support three 3rd party sites at its launch which include Peerflix, FilmCrave and Fuzz.com. Like a [Last.FM](http://crunchbase.com/organization/Last.FM) for video, music, movies and blogs, MatchMine seeks to help you discover your new favorite media. Although their are no direct competitors, it will be interesting to see if CBS, which acquired Last.FM in May of 2007, uses Last.FM's recommendation engine for its own TV content. Additionally, [StumbleUpon](http://crunchbase.com/organization/stumbleupon) functions comparably by recommending media based on your previous ratings of similar media.

Httprint

Series C in 2000
Httprint is a comprehensive service provider for the printing industry, offering enabling technology to streamline procurement and management processes for print buyers and sellers. With a background in outsourced print management, they provide customers with a team of experts to support or manage projects. Through their integrated website, buyers and suppliers can communicate and complete transactions online from anywhere in the world. Httprint's professional services team, comprised of print professionals, can assist buyers on all phases of the print transaction and are available for fully outsourced project management. Customers benefit from saving time and money by leveraging the expertise of httprint's team. Originally known as Landmark Productions, a brick and mortar print production company, httprint transitioned to the web in 2000, maintaining its reputation for serving companies lacking the resources or expertise for print services. Httprint serves as a centralized hub for purchasing activities, providing a total resource for buyers and suppliers in the print industry.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.